Synthetic phosphopeptide derived from human p21 around the phosphorylation site of Threonine 145.
Conjugation:
Unconjugated
Alternative Names:
Cyclin-dependent kinase inhibitor 1, CDK-interacting protein 1, Melanoma differentiation-associated protein 6, MDA-6, CDKN1A, CAP20, CDKN1, CIP1, MDA6, PIC1, SDI1, WAF1
It is now well established that cyclins play a positive role in promoting cell cycle transitions via their ability to associate with and activate their cognate cyclin-dependent kinases (Cdks). Cdk2 associates with cyclins A, D and E, and has been implicated in the control of the G1 to S phase transition in mammals. A novel Cdk-interacting protein, designated p21, Cip1 or WAF1, has been identified in cyclin A, cyclin D1, cyclin E and Cdk2 immunoprecipitates. p21 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk 2, cyclin E-Cdk2, cyclin D1-Cdk4 and cyclin D2-Cdk4 complexes. Expression of p21 is inducible by wildtype, but not mutant, p53. The mouse homolog of p21 is designated CAP20.
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).
Form:
Rabbit IgG, 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2
Application Dilute:
IHC: 1:50~1:200
Application Notes:
p-p21 (T145) polyclonal antibody detects endogenous levels of p21 protein only when phosphorylated at Thr145
* VAT and and shipping costs not included. Errors and price changes excepted
